LAURUS Labs
Chemistry for Better Living

April 24, 2025

To	To
The Corporate Relations Department **BSE Limited** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 **Code: 540222**	**The Listing Department** **National Stock Exchange of India Ltd.,** Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 **Code: LAURUSLABS**

Dear Sir / Madam,

Sub: **Investors / Analysts Presentation**

Please find enclosed the presentation to the Investors / Analysts on the Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2025, for the Investors / Analysts call scheduled on April 24, 2025 at 05.00 p.m. (IST), which was already intimated on April 10, 2025.

The presentation is also being uploaded on the website of the Company i.e., www.lauruslabs.com.

Please take the information on record.

Thanking you,

Yours sincerely,

For **Laurus Labs Limited**

VENKATESWAR REDDY GOGIREDDY
Digitally signed by VENKATESWAR REDDY GOGIREDDY
Date: 2025.04.24 15:12:12 +05'30'

G. Venkateswar Reddy
Company Secretary & Compliance Officer

Encl: A/a

Registered Office
Laurus Enclave, Plot Office 01, E. Bonangi Village,
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.
T +91 891 682 1101, 1102, **E** info@lauruslabs.com
F +91 891 682 1103, **W** lauruslabs.com
CIN : L24239AP2005PLC047518,

Corporate Office
2nd Floor, SDE Serene Chambers, Road No. 7,
Banjara Hills, Hyderabad - 500034, Telangana, India.
T +91 40 6659 4333, 3980 4333, 2342 0500 / 501,
F +91 40 6659 4320 / 3980 4320

LAURUS Labs
Chemistry for Better Living

FY 2025 Financial Results

24/04/2025

Safe Harbor Statement

This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward looking statements represent our judgment and future expectations concerning the development of our business, such statements reflect various assumptions concerning future developments and a number of risks, uncertainties and other important factors that could cause actual developments and results to differ materially from our expectations.

These factors include, but not limited to: 1) Change in the General market and macro-economic conditions for key global markets where we operate, 2) Governmental and regulatory trends, 3) Allocations of funds by the Governments in our key global markets, 4) Successful implementation of our strategy, R&D efforts, growth & expansion plans and technological changes, 5) Movements in currency exchange and interest rates, 6) Increase in the competitive pressures and Technological developments, 7) Changes in the financial conditions of third parties dealing with us, 8) Changes in laws and regulations that apply to our customers, suppliers and Pharmaceutical industry.

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results, performance or achievements of Laurus Labs Limited may vary materially from those described in the relevant forward-looking statements

The information contained in this presentation is current, and if not stated otherwise, made as of the date of this presentation. The Company undertakes no obligation to update or revise any information in this presentation as a result of new information, future events or otherwise.

This presentation is strictly confidential and may not be copied or disseminated, reproduced, re-circulated, re-distributed, published or advertised in any media, website or otherwise, in whole or in part, and in any manner or for any purpose without written approval from Laurus Labs Limited. Any unauthorized use, disclosure or public dissemination of information contained herein is prohibited.

This presentation is for information purpose only and is not a prospectus, a statement in lieu of a prospectus, an offering circular, an advertisement or an offer document under the Companies Act, 2013, as amended, or the rules made thereunder, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, or any other applicable law in India.

By accessing this presentation, you accept that this disclaimer and any claims arising out of the use of the information from this presentation shall be governed by the laws of India and only the courts in Telangana, India, and no other courts, shall have jurisdiction over the same.

Agenda

1 FY 2025 Corporate Overview

2 FY 2025 Financial Overview

3 FY 2025 Business Review & Strategy

LAURUS Labs
Chemistry for Better Living

1

Corporate Overview

FY 2025

FY 2025 – Enhanced performance on resilient Core business

Full Year 2025 in numbers

- **₹5,554 Cr** — Revenues +10%
- **55.4%** — Gross margin +3.7%
- **7,800 KL** — Reactor volume
- **7,042** — Employees +5%
- **₹1,115 Cr** — EBITDA margin: 20.1% (+4.2%)
- **₹659 Cr** — CAPEX 12% of Sales
- **2.3x** — Net debt / EBITDA -0.6x
- **2,634** — R&D & Quality Team

4Q 2025

- **₹1,720 Cr** — Revenues +19%
- **₹477 Cr** — EBITDA margin: 27.7% (+9.7%)

LAURUS Labs
Chemistry for Better Living

Accelerated excellence in a year of transformative progress

Transform Commercial potential

- Working in late phase & Commercial phase projects
- Reinforcing ties with Big pharma customers
- Eight Roads invest in Bio to build fermentation capacity
- Successful regulatory audits
- KRKA CMO deal, Manufacturing capability expansion

Elevate R&D engine

- CDMO focused new R&D facility operational leveraging advance PD capabilities for hybrid solutions
- Expanding application of cutting edge technology at scale; biocatalysis, flow chemistry, continuous hydrogenation
- Established commercial scale Peptide Synthesis capability
- New leadership hired to lead initiatives on Gene technology antibody Conjugates platforms

Healthy Financial execution

- Expanded margins both at Gross and EBITDA levels
- Capital deployments focused towards high return CMO/CDMO segments
- Net Debt stood at Rs.2,594 Cr

Securing ESG

- Inclusion in S&P Global Sustainability Yearbook 2025 & only company to be Named “Industry Mover” from Pharma industry
- Improved DJSI ESG score to 73 (+14pp)
- Signed near-term SBTi targets
- 26MW RE (Solar+Wind) purchase deal with Kurnool Renewables
- Multiple Industry Best Safety Practice awards

CDMO market – Maintaining high market momentum

Small molecule CDMO market is structurally growing due to increase in outsourcing

$80bn Global SM CDMO demand expected to grow **>7% CAGR** from 2023-28 vs. 5% in last 5 years

$2bn Indian CDMO potential to grow **>14% CAGR,** ahead of global market led by expanding service capabilities

Laurus is well positioned to compete as a efficient, and high quality One-Stop solution provider from Clinical stage Development to Manufacturing at Scale

- Comprehensive Technology Platform
- World Class Commercial infrastructure
- Proactive Investments in Capacities
- Rigorous IP protection
- Regulatory excellence

- Small molecules remains dominant modality representing +70% [1] of novel drug approval and holding high share in clinical pipeline
- Continued demand in CDMO service across health industry
- Demand for Integrated and Specialized capabilities with rising API complexity, long manufacturing lead times
- Tightening development timelines for oncology/orphan drugs, with many receiving expedited approvals
- Continuing supply chain de-risking by Big/Mid-pharma, increasing interest in early phase collaboration with trusted partners
- Tariff uncertainty creating short-term noise
- Pricing pressure from Inflation Reduction Act

1 Internal analysis, Based on data as of Dec 2024 , CDER, USFDA

Industry, Evaluate Pharma, BCG

FY 2025 – Outlook delivered



LAURUS Labs
Chemistry for Better Living

Business Division: Resilience through diversification, led by Integrated model

Strong cumulative performance; Declining ARV share

	CAGR % FY 20-25	FY 25	Revenue mix
CDMO[1]	+32%	+42%	28%
GENERICS[2]	+10%	+2%	72%

ARV revenue share declining & CDMO share more than doubled



Broad portfolio of Customers

Revenue by Customer location



Revenue by Customer



[1] includes Small Molecules & Bio business performance, [2] includes FDF and API business performance

LAURUS Labs
Chemistry for Better Living

Increase in asset turnover levels to drive future Revenues and Margin pick up



- Execution of significant CDMO project deliveries since mid-FY25
- Long manufacturing lead-times for Complex clinical compounds/Lower volumes translated into asset under-utilization and lower cost absorption (FY23 to mid-FY25)
- Gross margins healthy during period of lower utilization
- Asset turnovers projected to return to normalized levels over the next two years

* Indicative Average Asset Turnover (FY21-25) absorbing plant maintenance

LAURUS Labs
Chemistry for Better Living

Continuing organic investment to support long term growth

- Groundbreaking of microbial fermentation facility (Vizag) expected by June 2025
- CDMO capacity expansion completed across multiple sites in 2025 along w/new CDMO R&D, AH MB-3 & Bio pilot facility. Corp-science facility started operations in Q4
- Significant on-going investment in Continuous manufacturing
- FY25 CAPEX at ₹ 659 Cr; 12% of Revenue

Strategic high return API / CDMO portfolio supported by integrated DP



Phase-wise Split of Investments



7
On-going growth projects
(3 DS + 1 DP + 1 Bio + 2 Cell and Gene)

50%
of CAPEX added for growth FY22-25

90%
invested into large scale Manufacturing assets

>85%
Growth CAPEX in diversified portfolio

[1] Cumulative Net addition including CWIP, Land, ETP and plant maintenance till March 2025

LAURUS Labs
Chemistry for Better Living

Robust network of **15** 'D & M' Sites: Supporting Global clients with Unique Capabilities

7800 KL | Reactors volumes

9 Sites | CDMO Activity

1267 | Scientists

10 billion | Drug Product

240 KL | Fermentation

R&D center

R&D 1 with Kilo lab Hyderabad
DS/DP Development ❶

New R&D - Hyderabad
200,000sft - *Opened in Sep'24*
DS Development ❶

Microbial Fermentation

LB-1 & LB-2*, Bangalore ***+240 KL***
R&D and Manufacturing

Cell [1] and Gene Therapy

GMP facility 1, Mumbai [1]
CAR-T Development & Manufacturing

GMP facility 2, Mumbai [1]
CAR-T Development & Manufacturing

Gene therapy, Hyderabad
Development & Manufacturing

Small Molecules

Unit 1 & **3, Vizag *3600 KL***
API/DS Manufacturing ❶❷❸❹❺❻

Unit 5, Vizag ***161 KL***
DS Manufacturing ❶❷

Unit 2, Vizag *+10bn units*
FDF/DP Development & Manufacturing ❺❻

Unit 4, Vizag *+2000 KL*
API/DS Manufacturing ❶❷❸❺

Unit 6, Vizag ***1475 KL***
API Manufacturing ❷

LSPL 2, Vizag *+294 KL*
API/DS Manufacturing ❶❷❺

LSPL 4, Vizag ***+60 KL***
API/DS Manufacturing

Key Technology Platforms

❶ High potent
❷ Bio-catalysis
❸ Flow technology
❹ Trickle bed hydrogenation
❺ Continuous manufacturing
❻ Spray Drying

Site under expansion or construction

[1] Through our Associate company ImmunoACT, * Earlier R1 & R2

LAURUS Labs
Chemistry for Better Living

Commitment to “One Quality for all Markets” & Highest Compliance Standards

160 Quality audit completed in FY25: Regulatory # 14 & Customer # 146

54 Inspection passed by major Regulators (US FDA, WHO, EU EMA, and Japan PMDA)

1260+ Quality audits & Inspection by Global Customers, Regulators since inception

Regulatory audit & Share of audit from top Global Regulators[1]



Last US FDA inspection

Key Facilities	Key Regulatory Certifications	Date	# audits (since inception)	EIR Status
Kilo Lab – R&D	USFDA, TGA, KFDA, PMDA, ANVISA - Brazil	2024	5	✓
Unit 1	USFDA, TGA, MHRA, WHO-Geneva, PMDA, ANVISA	2024	7	✓
Unit 2	USFDA, WHO-Geneva, EMA	2023	5	✓
Unit 3	USFDA, WHO-Geneva, JAZMP-Slovenia, ANVISA	2024	5	✓
Unit 4	WHO-Geneva, USFDA	2025*	2	✓
Unit 5	USFDA	2022	1	✓
Unit 6	USFDA	2018	1	✓

* On 15th April 2025, USFDA has issued EIR status to Unit 4 API manufacturing facility in Vizag. The audit was conducted between 27-31 Jan 2025

LAURUS Labs
Chemistry for Better Living

R&D platform : Advancing Sustainable technology and Capability extension

Significant Updates

>75 R&D project* supported in FY25

40% Increase in projects on Bio-catalysis platform

30% Increase in Continuous Flow Reaction projects

- Solidifying position on Flow/Bio-catalysis platform. Executed ton-level project utilizing proprietary designed flow reactors at high temp/pressure
- CDMO R&D facility operational leveraging advanced PD capabilities
- Successfully executed on commercial scale Peptide Synthesizer
- Developed continuous hydrogenation technology (lab scale) + New capability building for drug candidates

> 48,000 m²
R&D Center

2634
Scientist & Quality Team

1267
R&D Scientist

90+
DS/DP launches

Strengthening technology platform applications and Process development with focus on delivering high quality CMO/CDMO development and manufacturing service to Global partners

* DS/DP together

LAURUS Labs
Chemistry for Better Living

Advancing ESG agenda and Enhancing competitive advantage

Significant updates

- EMS (ISO 50001) completed for multiple facilities
- Acquired 26% equity in Kurnool Renewables (SPV) for ₹ 35 Cr, enabling Co to access 26 MW of RE (solar+wind) on captive mode basis starting Dec-2026
- Continued application of Green technology, Continuous manufacturing platforms
- Multiple EHS best practice awards received

Further planned activities

- Product Life cycle assessment
- Carbon-neutral Biomass Boilers for LSPL intermediates /API units in Vizag

ESG Ratings

Sustainability Yearbook Member
Corporate Sustainability Assessment (CSA) 2024

Named First time in S&P Global Sustainability Yearbook 2025

SCIENCE BASED TARGETS
DRIVING AMBITIOUS CORPORATE CLIMATE ACTION

Committed to Near-term GHG targets

S&P Global ESG Score
73
Data Availability : Very High
Methodology Year: 2024

Improved S&P ESG Score Vs. 59/100 LY

MSCI ESG RATINGS BBB
CCC | B | BB | BBB | A | AA | AAA

Consecutive "BBB" ratings in FY22-25

PSCI
PHARMACEUTICAL SUPPLY CHAIN INITIATIVE

Joined PSCI, reaffirming commitment to responsible business practice and supply chain resilience

LAURUS Labs
Chemistry for Better Living

2

Financial Overview

FY 2025

FY 2025: Improving Core performance

FY25 Financial Summary

[₹ Crore]	FY25	FY24	Y-o-Y
Revenues	**5,554**	**5,041**	***10%***
Gross Margins	*55.4%*	*51.7%*	*3.7%*
EBITDA [1]	**1,115**	**798**	***40%***
% to Revenues	*20.1%*	*15.8%*	*4.3%*
Net Profit	**358**	**161**	***122%***
% to Revenues	*6.4%*	*3.2%*	*3.2%*
EPS (₹) [1]	**6.6**	**2.9**	***128%***
Operating Cash flow	**602**	**666**	***-10%***
Capex	**659**	**700**	***-6%***
Net Debt-to-EBITDA	**2.3x**	**2.9x**	***-21%***
ROCE	**9.7%**	**6.4%**	***+3.3%***

Comments

- Revenues : ₹ 5,554 Cr, increased 10% primarily driven by strong CDMO execution while generic FDF growth offset by lower API business
- Gross Margins : 55.4%, increased by 370 bps on better divisional mix
- R & D spends reported at ₹ 257 Cr (4.6% of Revenues) including CGT spends
- EBITDA : ₹ 1,115 Cr, increased by 40%
- EBITDA Margins : 20.1%, increased 430 bps Y/Y, due to improving revenue delivery and gradual step up in asset utilization
- Net Profits : ₹ 358 Cr, increased 122% Y/Y

- OCF declined despite positive EBITDA growth due to higher net working capital
- Net Debt largely inline and is likely to improve further due to increased sales
- Compressed ROCE due to negative operating leverage, higher CAPEX+WC Debt

1 EBITDA includes one-time gain of Rs 59 Cr related to Sale of Land parcel in 4QFY25, translating to ₹ 0.9 positive EPS impact (net of tax)

LAURUS Labs
Chemistry for Better Living

FY 2025: Strong CDMO execution, supported by FDF while API remain soft

FY25 Divisional Revenue Performance

[₹ Crore]	FY25	FY24	Y-o-Y
CDMO	**1,534**	**1,082**	***42%***
Small molecules	1,374	922	*49%*
Bio	160	160	*0%*
Generics	**4,020**	**3,959**	***2%***
API	2,438	2,545	*-4%*
FDF	1,582	1,414	*12%*
Total Revenues	**5,554**	**5,041**	***10%***
ARV Revenues*	2,559	2,506	*2%*

FY25 Divisional Mix



* Includes API and Formulation (FDF) combined revenues

LAURUS Labs
Chemistry for Better Living

FY 2025: Financial Position

FY25 Balance sheet

[₹ Crore]	FY25	FY24	Y-o-Y
Net Fixed assets (incl. CWIP)	**4,316**	**4,048**	**+268**
Goodwill and Intangibles	**266**	**265**	**+1**
Net Working Capital (A+B-C)	**2,985**	**2,457**	**+528**
A. Inventories	1,937	1,845	
B. Receivables	2,007	1,663	
C. Payables	959	1,051	
Other assets & liabilities *	**-501**	**-291**	**-210**
Cash and Cash Equivalents	**100**	**139**	**-39**
Equity	**4,473**	**4,111**	**+362**
Debt (current + non-current)	**2,693**	**2,507**	***+186***
Total Net Assets	**7,166**	**6,618**	***+548***

Increase in net fixed assets

Increase mainly in property, plant and equipment due to

- Investments in new R&D center for CDMO activities in Hyderabad site
- Building Intermediate/API manufacturing blocks at LSPL unit 2 & Unit 4, Drug Product line expansion and certain API block modification at Vizag site

Increase in net working capital

- Increase mainly due to a increase in inventories and accounts receivables

Increase in Other assets & liabilities

- Increase led mainly in customer advances and investment in KrKa Pharma JV

Increase in Net Debt

- Increase mainly in the working capital loans to support several CDMO project deliveries involving longer lead time. Long term debt remained stable

* Includes Current and non-current assets/liabilities (Provisions, Lease liabilities, Advance from customers, Deferred income tax, accrued corporate tax, etc)

4Q FY25: Higher revenues and better mix driving strong profitability growth

4Q FY25 Financial Summary

[₹ Crore]	3Q FY25	4Q FY25	4Q FY24	*Y-o-Y*	*Q-o-Q*
Revenues	**1,415**	**1,720**	**1,440**	***19%***	***22%***
Gross Margins	*56.9%*	*54.5%*	*49.8%*	*+4.7%*	*-2.4%*
EBITDA [1]	**285**	**477**	**259**	***84%***	***67%***
% to Revenues	*20.1%*	*27.7%*	*18.0%*	*+9.7%*	*+7.6%*
Net Profit	**92**	**234**	**76**	***208%***	***154%***
% to Revenues	*6.5%*	*13.6%*	*5.3%*	*+8.3%*	*+7.1%*
EPS (₹) [1]	**1.7**	**4.3**	**1.4**	***207%***	***153%***

Comments

- Revenues : ₹ 1,720 Cr, increased 19% primarily driven by strong CDMO and generic FDF partly offset by lower API business
- Gross Margins : 54.5%, increased by 470 bps on better divisional mix
- R & D spends reported at ₹ 66 Cr (3.8% of Revenues)
- EBITDA : ₹ 477 Cr, increased by 84% Y/Y
- EBITDA Margins : 27.7%, increased 970 bps Y/Y, due to improving revenue delivery and strong operating leverage
- Net Profits : ₹ 234 Cr, increased 208% Y/Y
- Interim Dividend of ₹ 0.80/- per share

1 EBITDA includes one-time gain of ₹ 59 Cr related to Sale of Land parcel in 4QFY25, translating to ₹ 0.9 positive EPS impact (net of tax)

4Q FY25: Continued CDMO momentum supported by Generic FDF

4Q FY25 Divisional Revenue Performance

[₹ Crore]	3Q FY25	4Q FY25	4Q FY24	Y-o-Y	Q-o-Q
CDMO	**448**	**490**	**265**	***85%***	***9%***
Small molecules	400	461	236	*95%*	*15%*
Bio	48	29	29	*0%*	*-40%*
Generics	**967**	**1,230**	**1,175**	***5%***	***27%***
API	531	686	745	*-8%*	*29%*
FDF	436	544	430	*27%*	*25%*
Total Revenues	**1,415**	**1,720**	**1,440**	***19%***	***22%***
ARV Revenues*	619	803	708	*13%*	*30%*

4Q FY25 Divisional Mix



* Includes API and Formulation (FDF) combined revenues

LAURUS Labs
Chemistry for Better Living

Summary Quarter Performance: Acceleration in growth momentum

Revenues



EBITDA & Gross Profit Margins



RoCE (ttm EBIT/Capital Employed)



Net Leverage (Net Debt/ ttm EBIDTA)



LAURUS Labs
Chemistry for Better Living

3

Business Review & Strategy

FY 2025

CDMO – Small molecules: Solidifying growth driven by enhanced capabilities

Revenue Growth



Comments

- >95% growth for Q4 and >49% growth for Full year mainly driven by several mid-to-late stage NCE deliveries and steady increase in sales from new manufacturing assets
- Sustained demand in high-value/complex small molecule offerings
- Multiple signings in late phase & commercial phase programs, reflecting more trust from the industry on our comprehensive technology platform, further solidifying growth potential
- In 2025, small molecules API reactor volumes enhanced by 15% & capacity steadily increasing. Animal health MB3 commenced operation in Q2 & Crop protection unit in Q4
- Continue to invest in Vizag site, new DS block at Unit-4, Animal health DS facility MB-4

LAURUS Labs
Chemistry for Better Living

CDMO – Small molecules additional updates

- Several RFPs received and multiple contract negotiations ongoing covering complex chemistries, biocatalysis, flow chemistry, peptides etc.
- CDMO pipeline continues to expand with shift towards increased Big pharma providing support for long term growth

>110

Active pipeline projects

>90

Human health projects (over 15 commercial incl. APIs + intermediates)

20

Clinical and commercial projects in Animal health and Crop science

Successfully commenced operations at New R&D in Nov 2024 located in Genome Valley, Hyderabad **To enhance clinical project reserves**

- Focus on efficient, flexible and high quality CDMO solution to global partners
- Best-in-Class capability in handling complex Drug synthesis & leading technology platform like flow, bio-catalysis, high potent, high pressure hydrogenation & continuous manufacturing
- Plan underway to expand site capabilities for advanced modalities/therapies utilizing bio catalysis technologies based on the client needs
- New site expected to create 800+ professional jobs overall next two years

LAURUS Labs
Chemistry for Better Living

BIO – Focus continues on building robust pipeline

Revenue Growth



* The investment received from Eight Roads Venture and F-Prime Capital, in Laurus Bio in the form of Compulsorily Convertible Preference shares (CCPS). Laurus Lab has agreed to co-invest ₹ 40 Cr before June 2025. Post transaction completion effective shareholding of Eights Roads to remain at 14% in Laurus Bio

Comments

- Healthy underlying revenue growth in 2025 driven by continued strong demand in AOF portfolio (CGT, MABs, Media)
- Diverse and potential longer term programs added to pipeline in CDMO services business
- ₹ 120 Cr tranche from Eight Roads completed*, total outlay ₹ 250 Cr planned on Fermentation site (Vizag) - to open by 2026 end
- Strong interest in enzyme engineering platform across small molecule clinical and commercial API projects

>180	1.5x	>60
Client supported in AOF and CDMO	Client base expansion over FY24	Active R&D projects

LAURUS Labs
Chemistry for Better Living

GENERICS – Impacted by soft API business, focus on differentiated portfolio

Revenue Growth



Global FDF filings	US	EU	Canada	ROW
Approved	35*	17	16	58
Pending	8	4	7	10
Total	**43**	**21**	**23**	**68**

* Includes 14 Tentative approvals in US

Comments

- Continued strong Q/Q growth ARV & DM led. However, soft FY delivery driven by prioritise API capacity allocation into attractive business opportunities + price erosion
- Multiple integrated CMO contract signed, supplies started. FDF manufacturing lines expansion on track – coming online by Dec-25
- Increased R&D resourcing planned in 2026 to enhance product pipeline + positive order booking converting to sales driving growth
- Recent US launches picking up pace following new contracting, closely monitoring US tariff situation
- DMF filings: 7 filed in FY25. Cumulatively, 90 filed till date
- Developed market FDF filings: 7 dossiers filed and 6 approvals received in FY25. Cumulatively, 87 product filed till date

LAURUS Labs
Chemistry for Better Living

KrKa Pharma, JV update – Collaboration progressing well

1st phase Investment [1] completed

- Cumulatively invested ₹ 215 Cr in JV (incl. Laurus ₹ 105 Cr and KrKa ₹ 110 Cr) in FY25, Completed land acquisition at Hyderabad (19 acre)
- Groundbreaking for FDF manufacturing facility by June-25 with focus to serve new markets including India
- **Planned Capabilities:** Highly potent/oncology OSD (OEB4/5 level) >150M unit/year and OSD (Tab/Caps) 10B units/year in two phases

Other key updates

- Portfolio evaluation for US market ongoing
- Capacity expansion ongoing at Vizag to address client immediate commercial needs – expanded lines handy by Dec-25, multiple products loaded into stability

1 KRKA Pharma Private Limited, a JV of the Company (51:49 share between KRKA and Laurus Labs)

ARV - Tough market environment; Maintained stable outlook while navigating risk

ARV^ business de-risking continues



Industry environment

- Continued funding for life saving medicines by Large buyers^
- Optimal capacity utilization, Competitive headwinds driving low industry margins
- DTG^ use to remain steady over the next several years; barrier to Long-acting ART implementation, proposed US aid cut for PrEP^

Our Priorities & Outlook 2026

- Sustained 1L products demand driving stable outlook
- Extensive pipeline to weather any future regimen switch
- API Capacity alignment to support customer demand and cost efficiency gains

ARV: Antiretroviral Drugs, DTG: Dolutegravir, ART: Antiretroviral therapy, Large Buyers includes PEPFAR and the Global Fund, PrEP: Pre-exposure prophylaxis

LAURUS Labs
Chemistry for Better Living

Cell therapy – Prioritise expanding CAR-T utilization

NexCAR19™
Actalycabtagene autoleucel

6x Revenue increase



300 patients treated since Nov'23 launch

73% response rate, r/r BCL[1] results published in Lancet 2025 driven by greater affordability to global alternatives

- Expanding hospital network > 80 Hospital centers
- Encouraging data (efficiency/safety) on NexCAR presented at ASH 2024 demonstrating strong clinical delivery success in limited resource setting
- Acceleration of multiple R&D projects, NexCAR Phase-1 trials in pediatric initiated
- **BCMA[2]:** received approval to start Phase 1 India)

2nd GMP facility (Navi Mumbai)

- Commencing operations in mid 2025
- Expect to add 2,500 treatment capacity

[1] Relapsed / Refractory BCL= B cell lymphoma; [2] Indication for relapsed /refractory Multiple Myeloma

LAURUS Labs
Chemistry for Better Living

Gene therapy – Focus on capability building continues

- New President appointed to lead Gene R&D and manufacturing initiatives and also explore other emerging technology platforms/therapeutics
- >US$20mn CAPEX investments committed in building GMP facility (Hyderabad) – target completion by March 2026
- Process development work initiation by mid 2025 based on GMP design consideration
- Capabilities planned: Plasmids DNA and vectors of various types including AAV, lentiviral and Bio-conjugates



LAURUS Labs
Chemistry for Better Living

Appendix

LAURUS Labs
Chemistry for Better Living

Financial Highlights FY 2019-25

Revenues



EBITDA & Gross Profit Margins



RoCE (ttm EBIT/Capital Employed)



Net Leverage (Net Debt/ ttm EBIDTA)



LAURUS Labs
Chemistry for Better Living

Earnings call details

Laurus Labs Results Conference Call to be held on Thursday, 24 April 2025 at 5:00 PM IST

Dial – In – Details	
Universal Dial-In	+91 22 6280 1384
India Local access Number	+91 22 7115 8285
Singapore	+800 1012045
Hong Kong	+800 964448
USA	+1 866 746 2133
UK	+0808 101 1573

Click below to Express Join with Diamond Pass

Click here to register

Additional Information

As a research-driven pharmaceutical manufacturing organization, Laurus Labs has been developing and assisting its client organizations to succeed in innovative medicines that globally enhance the health outcomes for patients. Since our inception in 2005, we have been developing and manufacturing APIs and Intermediates. We have global leadership position in APIs, including anti-retroviral, oncology, cardiovascular, and gastro therapeutics. Our position was strengthened by our backward-integration and strong regulatory compliance across all operations. We emerged as one of the most trusted CMO and Contract Development and Manufacturing Organization (CDMO) service provider to Global Innovators from drug development phase to commercial manufacturing.

Laurus employs 7000+ people, including around 1,250+ scientists across 15 development & manufacturing sites approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc. During FY2025 Laurus generated ₹ 5,554 crore in annual revenue and is listed on the BSE (Bombay Stock Exchange) and the NSE (National Stock Exchange) in India. Laurus' proactive stance to conduct business with utmost Transparency, Integrity and Respect for environment & communities have earned it a place in Governance benchmark, consistently Certified Great Place to Work and Rated “BBB” by leading MSCI ESG Ratings. Corporate Identification No: L24239AP2005PLC047518.

Investor relations

Vivek Kumar

T: +914066594366
E: investorrelations@lauruslabs.com
E: vivek.k@lauruslabs.com

For more information
Please visit our website www.lauruslabs.com

LAURUS Labs
Chemistry for Better Living

Please consider the environment before printing this Presentation